文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

限制脓毒症急性肾损伤进展:研究方案与试验模拟

Limiting Acute Kidney Injury Progression In Sepsis: Study Protocol and Trial Simulation.
PubMed 文献 · Crit Care Med · 2021-01-01
一句话结论在脓毒症或脓毒性休克且入组时无2/3期急性肾损伤的重症患者中,系列尿[组织金属蛋白酶抑制物-2]•[胰岛素样生长因子结合蛋白7]检测可将72小时内急性肾损伤进展≥2期、死亡或透析的风险从6%分层至41%(Sapphire)及从14%分层至46%(ProCESS)。

本文描述「限制脓毒症急性肾损伤进展」研究方案:一项4期、多中心、适应性、随机对照试验,并利用Sapphire与ProCESS两项既往研究的患者级数据进行试验模拟。主要终点为入组后72小时内急性肾损伤进展≥2期、死亡或透析。Sapphire模拟中203例脓毒症患者45例(22%)达到终点,ProCESS模拟中607例脓毒性休克患者144例(24%)达到终点。两模拟中,按方案建议的尿[组织金属蛋白酶抑制物-2]•[胰岛素样生长因子结合蛋白7]模式可将终点风险分层:Sapphire从6%(三次阴性检测)至41%(符合最高级别保肾脓毒症集束化治疗者),ProCESS从14%(两次阴性检测)至46%(符合最高级别保肾脓毒症集束化治疗者)。

要点

  • 试验针对脓毒症或脓毒性休克、入组时无2/3期急性肾损伤证据的ICU患者,主要终点为72小时内急性肾损伤进展≥2期、死亡或透析。
  • Sapphire模拟中203例脓毒症患者45例(22%)达到主要终点;ProCESS模拟中607例脓毒性休克患者144例(24%)达到主要终点。
  • Sapphire模拟中,尿[组织金属蛋白酶抑制物-2]•[胰岛素样生长因子结合蛋白7]模式将终点风险从6%(三次阴性检测)分层至41%(符合最高级别保肾脓毒症集束化治疗者)。
  • ProCESS模拟中,同一模式将终点风险从14%(两次阴性检测)分层至46%(符合最高级别保肾脓毒症集束化治疗者)。
  • 作者认为该方案算法在识别适合接受保肾脓毒症集束化治疗的高危个体方面可行。

适用人群与场景

  • 学术与社区ICU中脓毒症或脓毒性休克、入组时无2/3期急性肾损伤证据的危重患者。

诊断标准与关键阈值

  • 主要终点:入组后72小时内急性肾损伤进展≥2期、死亡或透析。
  • 尿[组织金属蛋白酶抑制物-2]•[胰岛素样生长因子结合蛋白7]为细胞周期停滞的尿液生物标志物,可在临床表现出现前检测急性肾损伤。

处置流程与药物剂量

  • 试验设计为根据系列尿[组织金属蛋白酶抑制物-2]•[胰岛素样生长因子结合蛋白7]检测结果,按国际指南应用逐级升级的保肾脓毒症集束化治疗。

研究设计与关键结果

  • 研究类型:4期、多中心、适应性、随机对照试验的方案描述,并利用Sapphire与ProCESS两项既往研究的患者级数据进行试验模拟;场景为学术与社区ICU。
  • Sapphire模拟:203例脓毒症患者中45例(22%)达到主要终点;尿[组织金属蛋白酶抑制物-2]•[胰岛素样生长因子结合蛋白7]模式将终点风险从6%(三次阴性检测)分层至41%(符合最高级别保肾脓毒症集束化治疗者)。
  • ProCESS模拟:607例脓毒性休克患者中144例(24%)达到主要终点;同一模式将终点风险从14%(两次阴性检测)分层至46%(符合最高级别保肾脓毒症集束化治疗者)。

证据类型、等级与局限

  • 证据类型:研究方案与试验模拟(基于Sapphire和ProCESS患者级数据)。
  • 作者结论:模拟结果证实尿[组织金属蛋白酶抑制物-2]•[胰岛素样生长因子结合蛋白7]可识别72小时内进展至中/重度急性肾损伤、死亡或透析风险不同的患者,方案算法在识别适合接受保肾脓毒症集束化治疗的高危个体方面可行。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文为研究方案与模拟,未据此给出床旁推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To describe study design considerations and to simulate a trial of biomarker-guided sepsis management aimed to reduce acute kidney injury (acute kidney injury). Tissue inhibitor of metalloproteinases-2 and insulin-like growth factor-binding protein 7, urinary biomarkers of cell-cycle arrest, and indicators of kidney stress can detect acute kidney injury before clinical manifestations. We sought to determine the event rates for acute kidney injury as a function of serial measurements of urinary (tissue inhibitor of metalloproteinases-2)•(insulin-like growth factor-binding protein 7) in patients at risk of sepsis-associated acute kidney injury, so that an escalating series of kidney-sparing sepsis bundles based on international guidelines could be applied.

DESIGN: We described the study protocol of "Limiting acute kidney injury Progression In Sepsis," a phase 4, multicenter, adaptive, randomized controlled trial. We performed simulations to estimate the rates for the trial's primary endpoint using patient-level data from two previous studies (Sapphire and Protocolized Care for Early Septic Shock).

SETTING: Academic and community ICUs.

PATIENTS: Critically ill patients with sepsis or septic shock, without evidence of stage 2/3 acute kidney injury at enrollment.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: Our primary endpoint is progression of two or more stages of acute kidney injury, death, or dialysis within 72 hours after enrollment. In the Sapphire simulation, 45 of 203 patients (22%) with sepsis met the endpoint. In Protocolized Care for Early Septic Shock, 144 of 607 patients (24%) with septic shock met the endpoint. In both simulations, (tissue inhibitor of metalloproteinases-2)•(insulin-like growth factor-binding protein 7) patterns, suggested by Limiting acute kidney injury Progression In Sepsis protocol, stratified the risk for the endpoint from 6% (three negative tests) to 41% (for patients eligible for the highest level of kidney-sparing sepsis bundle) in Sapphire, and 14% (two negative tests) to 46% (for the highest level of kidney-sparing sepsis bundle) in Protocolized Care for Early Septic Shock.

CONCLUSIONS: Findings of our Limiting acute kidney injury Progression In Sepsis trial simulation confirmed that (tissue inhibitor of metalloproteinases-2)•(insulin-like growth factor-binding protein 7) could identify patients with different rates of progression to moderate/severe acute kidney injury, death, or dialysis in 72 hours. The Limiting acute kidney injury Progression In Sepsis protocol algorithm is therefore feasible in terms of identifying suitably high-risk individuals for kidney-sparing sepsis bundle.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Molinari L, Heskia F, Peerapornratana S, et al. Limiting Acute Kidney Injury Progression In Sepsis: Study Protocol and Trial Simulation. Crit Care Med. 2021. PMID: 33927121. doi:10.1097/CCM.0000000000005061

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。